Ellevest, Inc. Affimed N.V. Transaction History

Ellevest, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	SELL	$1.1 - $2.45 $123 - $274	-112 Reduced 79.43%	29 $0
Q3 2022 Nov 02, 2022	SELL	$1.96 - $3.32 $229 - $388	-117 Reduced 45.35%	141 $0
Q2 2022 Jul 18, 2022	SELL	$2.27 - $4.86 $2 - $4	-1 Reduced 0.39%	258 $1,000
Q1 2022 Apr 19, 2022	BUY	$3.69 - $5.65 $298 - $457	81 Added 45.51%	259 $1,000
Q4 2021 Jan 24, 2022	BUY	$5.37 - $7.07 $955 - $1,258	178 New	178 $1,000
Q3 2021 Oct 19, 2021	SELL	$5.54 - $7.51 $1,562 - $2,117	-282 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$7.78 - $11.4 $1,921 - $2,815	247 Added 705.71%	282 $2,000
Q1 2021 May 03, 2021	BUY	$5.12 - $8.48 $179 - $296	35 New	35 $0
Q2 2020 Jul 06, 2020	SELL	$1.58 - $4.63 $571 - $1,676	-362 Closed	0 $0
Q1 2020 Apr 13, 2020	BUY	$1.44 - $3.02 $521 - $1,093	362 New	362 $1,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.